DFM Funding Monitor

Acceleration of the world’s first autotaxin inhibitor for the treatment of pancreatic cancer (PDAC)broad

CURE-PDAC · Horizon Europe grant · 2022-10-01–2025-03-31

EC contribution

€2,500,000

Total cost

€5,906,503

Beneficiaries

1

About the data

Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →

Objective

iOnctura is a clinical stage biopharmaceutical company dedicated to delivering innovative cancer treatments to patents with unmet medical needs. iOnctura’s unique pipeline of drugs unlock mechanisms at the tumour-stroma-immune (T-S-I) interface, a multi cell-network that is responsible for driving tumour growth and survival as well as treatment resistance.Pancreatic cancer is one of the most lethal cancers associated with devastating impact on the quality of life of patients; current treatments are largely ineffective and there is a need for game-changing therapies. IOA-289, is a first in class autotaxin (ATX) inhibitor that tackles cancer growth and spread by affecting core mechanisms at the T-S-I interface.The EIC Accelerator funding for CURE-PDAC will allow iOnctura to accelerate the clinical development of IOA-289 as a treatment for pancreatic cancer through Phase I/II clinical trials, reach a major value inflection point and attract further financial investment into the company.

Beneficiaries (1)

Organisation	Country	Role	EC contribution	SME
IONCTURA BV	NL	coordinator	€2,500,000	Yes

Get the EU Defence Funding Calendar — free

The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.

Get the calendar

Yes — subscribe me to DFM Analysis, the free weekly briefing on European defence funding, and send me the monthly funding calendar. Unsubscribe anytime.

Website

We store your email to send the calendar and the weekly DFM Analysis briefing. Nothing else. Unsubscribe anytime.

Or browse all open defence & dual-use calls on the funding calendar →

Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.